Last reviewed · How we verify

Levosert-20 — Competitive Intelligence Brief

Levosert-20 (Levosert-20) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intrauterine contraceptive system (IUS). Area: Contraception / Gynecology.

phase 3 Intrauterine contraceptive system (IUS) Progesterone receptor (local uterine effect) Contraception / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Levosert-20 (Levosert-20) — Uteron Pharma S.A.. Levosert-20 is a levonorgestrel-releasing intrauterine system designed to provide long-acting contraception and reduce menstrual bleeding.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Levosert-20 TARGET Levosert-20 Uteron Pharma S.A. phase 3 Intrauterine contraceptive system (IUS) Progesterone receptor (local uterine effect)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intrauterine contraceptive system (IUS) class)

  1. Uteron Pharma S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levosert-20 — Competitive Intelligence Brief. https://druglandscape.com/ci/levosert-20. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: